Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by V. Mueller
Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis
HIGHLIGHTS • Tucatinib combination shows continued prolongation of overall survival in patients with HER2+ metastatic breast cancer. • Overall survival benefit was consistent across all prespecified subgroups, including patients with brain metastases. • The tucatinib combination was well-tolerated with a low rate of discontinuation due to adverse events (5.9%).
Meeting the looming policy challenge of sea-level change and human migration
Minimizing the adverse consequences of sea-level change presents a key societal challenge. New modelling is necessary to examine the implications of global policy decisions that determine future greenhouse gas emissions and local policies around coastal risk that influence where and how we live. Fig. 1: Migration under sea-level change and policy scenarios. References 1. Clark, P. U. et al. Nat. Clim. Change 6, 360–369 (2016). 2. Rigaud, K. K. et al.
Climate Migration
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Coastal climate change, soil salinity and human migration in Bangladesh
Climate change is not only altering weather patterns but also accelerating sea-level rise, leading to increased inundation and saline contamination of soils. Given projected sea-level rise, it is imperative to examine the extent to which farmers in coastal Bangladesh can adapt by diversifying economic activities before resorting to migration within and across borders.
Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)
Background: Real-world data exploring effectiveness of treatments following demonstrated efficacy in phase III trials are becoming increasingly important, especially for regulatory bodies and payers. Pooling outcome and adverse-event (AE) data from non-interventional studies enables more accurate estimation of real-world effectiveness and safety in clinically important subgroups.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with V.
Contact V., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack